Novartis Vaccines & Diagnostics, Gmbh

Chiron Corporation

Novartis Ag

Ryan N Constantine

Weibo Wang

Liana Marie Lagniton

Paul A Renhowe

Savithri Ramurthy

Sabina Pecchi

Sharadha Subramanian

Paul Andrew Barsanti

David Duhl

Kenneth Walter Bair

Tinya Abrams

Annette Olga Walter

Kris Mendenhall

Nathan Brammeier

Megan C Phillips

Hong Yang

Mark Knapp

Eric J Martin

Rama Jain

Elisa Jazan

Elizabeth J Mieuli

Rustum Boyce

Anu Sharma

Kelly Wayman

Vincent P Le

Kay Huh

Manoj C Desai

Matthew T Burger

Yia Xia

Yi Xia

Rustum S Boyce

Liana Marie Lagnition

Xia Yia

Kris G Mendenhall

Annette O Walter

Tinya J Abrams

Nathan M Brammeier

The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula: 

Substituted imidazole derivates

Substituted imidazole derivatives

Quinazolinone compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the quinazolinone compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the quinazolinone compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.

Quinazolinone compounds as anticancer agents

The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses of the compounds. The compounds of the invention have the following general formula: 

Substituted imidazole compounds as KSP inhibitors

The present invention relates to compounds that are useful for treating cellular proliferative diseases, for treating disorders mediated, at least in part, by KSP, and for inhibiting KSP. The invention also related to pharmaceutical compositions comprising such compounds, methods of treating cancer by the administration of such compositions, and processes for the preparation of the compounds. Compounds of the invention have the following formula: 

Mitotic kinesin inhibitors

The present invention relates to new substituted quinoline compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula: 

Substituted quinoline derivatives

Heteroaryl-fused pyrimidinyl compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the heteroaryl-fused pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the heteroaryl-fused pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.

Heteroaryl-fused pyrimidinyl compounds as anticancer agents

Pyridin[1,2-a]pyrimidinyl compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the pyridino[1,2-a]pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the pyridino[1,2-a]pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.

Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents

Growing community of inventors

Oakland, CA, United States of America

Ryan N Constantine